NIVEL, Netherlands Institute for Health Services Research, PO Box 1568, 3500 BN Utrecht, the Netherlands.
BMC Health Serv Res. 2010 Feb 22;10:45. doi: 10.1186/1472-6963-10-45.
Little is known about the role European patient organisations play in the process of deciding on reimbursement for medicines. Therefore we explore the current role of patient organisations in the process of reimbursement for medicines in Western Europe. We focus in particular on collaboration between patient organisations and the pharmaceutical industry in this respect.
Sixty-eight patient organisations representing seven medical conditions, from ten Western European countries, were asked to participate in the study. The participating organisations reported their experiences in a web-based questionnaire.
Twenty-one patient organisations completed the questionnaire (response rate: 31%), of which ten (47.6%) demanded reimbursement for medicines. Organisations demanding reimbursement were larger than those not demanding reimbursement. The main aim of these organisations was to create better accessibility of medicines for patients. Most organisations limited themselves to single actions. Only two engaged in multiple actions. Almost all organisations had general policies on cooperation with the pharmaceutical industry, with autonomy as the key feature. The patient organisations said they were reasonably successful and almost always satisfied with their own role in the reimbursement process.
Our study has found that the role of European patient organisations in the reimbursement process still seems limited, especially for small patient organisations.
关于欧洲患者组织在药品报销决策过程中所扮演的角色,人们知之甚少。因此,我们探讨了患者组织在西欧药品报销过程中的当前作用。我们特别关注在这方面患者组织与制药行业之间的合作。
我们邀请了来自十个西欧国家的代表七种疾病的 68 个患者组织参与研究。参与的组织通过网络问卷报告了他们的经验。
21 个患者组织完成了问卷(回应率:31%),其中 10 个(47.6%)要求报销药品。要求报销的组织比不要求报销的组织更大。这些组织的主要目的是为患者创造更好的药物可及性。大多数组织只采取单一行动。只有两个组织采取了多种行动。几乎所有组织都对与制药行业的合作有一般性政策,自主性是关键特征。患者组织表示,他们在报销过程中的作用相当成功,几乎总是对自己的角色感到满意。
我们的研究发现,欧洲患者组织在报销过程中的作用似乎仍然有限,特别是对于小型患者组织。